NEW YORK, Oct. 16 - Orchid Biosciences has withdrawn a proposed follow-on public offering of over 21/2 million shares of new stock, the Princeton, N.J. company announced Monday.

The manufacturer of SNP scoring technology filed the follow-on public offering with the Securities and Exchange Commission September 22. The total offering was valued at $126,143,500, according to the filing, and included a total of 4,025,000 shares of common stock: the 2 1/2 million new shares, one million existing shares, and additional " green shoe" shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.